AOD-96045mg
As, Cd, Pb, Hg: not detected
Screens the vial for arsenic, cadmium, lead and mercury.
Batch AOD-CA-26I-05 · this lot
View heavy metals report →<1 EU/Vial.
Measures bacterial endotoxin present in the material.
Batch AOD-CA-26I-05 · this lot
View endotoxin report →Endotoxin and heavy-metals testing is done periodically on selected batches to verify quality — not on every batch. Each result applies to the batch shown.
AOD-9604 Canada — 5 mg Lyophilized Vials
Growth Hormone Fragment
Also known as hGH fragment 176–191
AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment (176–191) of human growth hormone, studied in research for lipolytic-pathway activity.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off vials.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment (176–191) of human growth hormone, studied in research for lipolytic-pathway activity.
Experimental models examine its influence on fat metabolism without the growth-promoting signaling of full-length GH.
AOD-9604 reproduces the lipolytic domain of human growth hormone while lacking the regions associated with insulin-like growth effects. Research has examined its action on lipid metabolism, including stimulation of lipolysis and inhibition of lipogenesis in cellular and animal models.
Studies have also evaluated its profile in cartilage and joint research models under structured conditions.
AOD-9604 was developed from research mapping the lipolytic activity of growth hormone to its C-terminal fragment. The synthetic peptide was characterized to retain fat-metabolism activity independent of GH receptor growth signaling.
Subsequent studies investigated metabolic and musculoskeletal research applications.
Research into AOD-9604 focuses on lipid-metabolism and GH-fragment models. Frameworks evaluate lipolytic and antilipogenic signaling and musculoskeletal endpoints under controlled in vitro and preclinical conditions.
3 of the 4 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Heffernan 2001, Cox 2015. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Heffernan 2001. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on cartilage or joint. This heading marks where AOD-9604 is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Addressed on this page by Ng 2000. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
The references section of this page cites 3 primary papers published between 2000 and 2015 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for AOD-9604, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
AOD-9604 is also referred to as AOD, and technically as hGH fragment 176–191.
AOD-9604 is commonly described online in connection with weight loss, appetite suppression and fat reduction. In the research literature the same compound is filed under lipid-metabolism and lipolysis models, GH-fragment pharmacology and cartilage and joint research frameworks.
The 3 papers cited on this page, published between 2000 and 2015 (1 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for AOD-9604 is per lot, not per product. The current 5mg lot AOD-CA-26I-05 returned 99.905% purity, 5.38 mg measured, 107.6% of the labelled 5 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is AOD-9604; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for AOD-9604, this lot measured 107.6% of its labelled 5 mg. Both numbers are published for every lot, whichever way they fall.
The lot code printed on the vial matches the code on the certificate for AOD-9604. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy AOD-9604 in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
AOD-9604 is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 16 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of aod 9604. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Related
Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$59.95CAD
Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$34.95CAD
Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$54.95CAD
Out of stockPeptides
Long-Acting Amylin Analogue · 5 & 10 mg Cagrilintide is a synthetic peptide developed for controlled laboratory research involving amylin receptor signaling systems. It is structurally designed to interact with amylin-associated pathways within experimental environments.
CAG-CA-26A-0199.446%
5.62 mg / 5 mg
$69.95CAD
